Zhonghua Zhong Liu Za Zhi. 2021 Oct 23;43(10):1016-1026. doi: 10.3760/cma.j.cn112152-20210714-00513.
The morbidity and mortality of prostate cancer ascend yearly, which seriously threatens the health of the male population. Bone is the main metastasis site of prostate cancer, with bone metastases and skeletal-related events (SREs) occuring in more than 70% of patients with advanced prostate cancer. Bone metastases and the resulting SREs, such as spinal cord compression and pathological fracture, seriously affect the life quality of the patients. Although the active treatments of the primary disease is important, the application of bone-modifying agents to prevent SREs cannot be overlooked. However, there is no standard treatment procedure for the bone metastasis of prostate cancer at present. According to the clinical status, the Genitourinary Oncology Committee of Chinese Anti-cancer Association formulated this consensus, which integrated clinical evidence and real world clinical practices in China and abroad, to help clinicians make more accurate diagnosis and treatment for the bone metastases of prostate cancer with multidisciplinary strategies.
前列腺癌的发病率和死亡率逐年上升，严重威胁男性人群的健康。骨是前列腺癌的主要转移部位，超过70%的晚期前列腺癌患者会发生骨转移和骨相关事件（SREs）。骨转移及由此产生的SREs，如脊髓压迫和病理性骨折，严重影响患者的生活质量。虽然对原发性疾病的积极治疗很重要，但应用骨改良药物预防SREs也不容忽视。然而，目前前列腺癌骨转移尚无标准的治疗程序。中国抗癌协会泌尿生殖肿瘤专业委员会根据临床现状制定本共识，整合国内外临床证据和真实世界临床实践，以帮助临床医生采用多学科策略对前列腺癌骨转移进行更准确的诊断和治疗。
